FOR IMMEDIATE RELEASE -- July 13, 2009 – Los Angeles, CA – Haloteco announced today that it is conducting a nationwide voluntary recall of the company's product sold under the name Libipower Plus.
Haloteco is conducting this recall after being informed by the representative of the Food and Drug Administration (FDA) that lab analysis of Libipower Plus samples found that the product contained Tadalalafil which is the active ingredient of FDA approved drugs for Erectile Dysfunction (ED). The product label doesn’t states it contain tadalafil. The undeclared ingredients may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Additionally, the product may cause side effects, such as headaches and flushing.
Libipower Plus is sold as a 1 capsule blister pack through distributors and retail stores in California.
Customers who have this product in their possession should stop using it immediately and contact their physician if they have experienced any problems that may be related to taking this product. Any adverse events that may be related to the use of this product should be reported to FDA's MedWatch Program by phone at 1-800-FDA-1088 or by fax at 1-800-FDA-0178 or by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787.
Consumers with questions may contact Haloteco Monday through Friday 8:00 am to 5:00 pm at (213) 820-9523. Haloteco is taking this voluntary action because it is committed and is always concerned with the health of persons who have consumed this product. Haloteco is working closely with the FDA in the recall process. It sincerely regrets any inconvenience to consumers.